You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Home / Tests / Sexual Health / Xpert CT/NG

Xpert® CT/NG

Accurate, reliable and fast detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in 90 minutes

Ordering Info

The Need


  • According to the European Centers for Disease Control over 400,000 cases of Chlamydia trachomatis (CT) and 89,239 cases of gonorrhoea were reported in 2017.1,2 Gonorrhoea is the second most notified sexually transmitted infection (STI) in the EU/EEA after chlamydia.2
  • Men who have sex with men (MSM) accounted for almost half of the reported cases (47%) in 2017.
  • Infections with extensively drug-resistant (XDR) Neisseria gonorrhoeae displaying resistance to ceftriaxone and high-level resistance to azithromycin reported by the UK and Australia.3
  • Routine screening on an annual basis is recommended for all sexually active females aged <25 years and extend to young men in some countries.4
  • Screening of sexually active young males should be considered in clinical settings serving high risk populations (e.g. MSM).5

What would help laboratories offering CT/NG testing?

  • Accurate, reliable, and reproducible tests
  • Enable onsite consultation & treatment of patients
  • Less time preparing samples and reagents
  • Shorter time to result
  • More test choices, fewer platforms

(1) European Centre for Disease Prevention and Control, Gonorrhoea - Annual Epidemiological Report for 2017, April 2019, available at: https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2017-chlamydia-infection.pdf
(2) Gonorrhoea Annual Epidemiological Report for 2017, available at: https://ecdc.europa.eu/sites/portal/files/documents/gonorrhoea-annual-epidemiological-report-2017.pdf
(3) Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia, 7 May 2018, available at: https://ecdc.europa.eu/sites/portal/files/documents/RRA-Gonorrhoea%2C%20Antimicrobial%20resistance-United%20Kingdom%2C%20Australia.pdf
(4) 2015 European guideline on the management of Chlamydia trachomatis infections. Euro Surveill. 2015;20(48):30080.
(5) 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013 Feb;24(2):85-92.

The Solution


  • Now anyone can run a CT/NG test with confidence. Each test cartridge contains everything you need, including three controls to ensure test integrity and performance. With Xpert® CT/NG, same-day patient consultation and treatment are now practical for clinicians.

On-demand CT/NG testing — a next generation solution:

  • Sample adequacy control confirms patient sample is genuine
  • CT target unique to Cepheid; selected for superior inclusivity
  • Double your confidence with two independent NG targets
  • More tests than any platform

The Impact


  • Speed and single-test confidence to make the most efficient use of your highly trained resources. Accelerate your laboratory’s workflow with on-demand, random-access flexibility. Combine performance with the ability to run other tests (such as GBS, MRSA, C. difficile, and Flu) on the GeneXpert System to achieve proven increase in overall laboratory level service.
  • Shift your lab from reactive to proactive
  • Achieve same-day containment and improve patient management
  • Deliver same-day results to clinicians with a 90 minute, on-demand test
  • Contact patient faster
  • Help more patients live healthier lives

/Site Images/Tests/CTNG-impact.png

Impact on Patient Pathway

Ordering Info


Xpert® CT/NG

50 Ready-To-Use Individual Kits

Catalog #: SWAB/A-50

Xpert® CT/NG

50 Ready-To-Use Individual Kits (to be launch shortly – Sept.)

Catalog #: SWAB/G-50

Xpert® CT/NG

50 Ready-To-Use Individual Kits

Catalog #: URINE/A-50

Xpert® CT/NG

Number of Tests: 10

Catalog #: GXCT/NGX-CE-10

Xpert® CT/NG

Number of Tests: 120

Catalog #: GXCT/NGX-CE-120

Educational Materials

Back to Top